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Abstract
Cost-of-illness studies (COI) can identify and measure all the costs of a particular disease, including the direct,
indirect and intangible dimensions. They are intended to provide estimates about the economic impact of costly
disease. Alzheimer disease (AD) is a relevant example to review cost of illness studies because of its costliness.The
aim of this study was to review relevant published cost studies of AD to analyze the method used and to identify
which dimension had to be improved from a methodological perspective. First, we described the key points of cost
study methodology. Secondly, cost studies relating to AD were systematically reviewed, focussing on an analysis of
the different methods used. The methodological choices of the studies were analysed using an analytical grid
which contains the main methodological items of COI studies. Seventeen articles were retained. Depending on the
studies, annual total costs per patient vary from $2,935 to $52, 954. The methods, data sources, and estimated cost
categories in each study varied widely. The review showed that cost studies adopted different approaches to
estimate costs of AD, reflecting a lack of consensus on the methodology of cost studies. To increase its credibility,
closer agreement among researchers on the methodological principles of cost studies would be desirable.
Keywords: Alzheimer disease, Cost study, Dementia, Economic, Evaluation, Review
Review
Introduction
Cost-of-Illness (COI) studies aim to identify and measure
all the costs of a disease [1]. They describe and estimate
the economic burden of a specific disease to a society, and
therefore the savings that could be done if the disease
were to be eradicated [2]. COI studies as decision making
tool has been debated, but they may be useful by educa-
ting, informing and enlightening policy makers in plan-
ning and financing [3]. COI studies are particularly
relevant in chronic diseases that weigh heavily on health
expenditures. Dementia is characterized by a gradual and
irreversible impairment of the intellect, memory, and per-
sonality. Alzheimer disease (AD) accounts for 60% to 80%
of all dementia cases and its prevalence will increase with
the life expectancy growth [4]. There are 35, 6 million de-
mented people in 2011, increasing to 115,4 million by
2050 [5]. Disease worldwide costs were US$ 604 billion in
2011, which 84% were attributable to informal and formal
costs. COI studies are the initial step in an economic
evaluation. Few cost-effectiveness analyses in AD drug
treatment show divergent results in costs saving [6,7],
probably because of different methodologies. So, it is ne-
cessary to accurately assess AD costs to show the potential
economic impact of new therapeutic or preventive stra-
tegies. Three articles were previously published on the
methodology of AD costs [8-10], but they were either
focus on European studies including other dementia (not
on AD specifically), or focus on informal costs and not
focus on COI studies. This study aims to review relevant
published AD COI studies, to analyze the methods used
and to identify the points that should be improved in
order to obtain convincing results from a methodological
perspective. First, we provided a general description of the
COI method. And then, we systematically reviewed AD
costs studies, analyzing the different methods used.
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Methods
Cost study
To conduct a COI study, it is necessary to define di-
sease, epidemiological approach, type of costs, and study
perspective. Subsequently, resource consumption data
and unit costs can be gathered, and the results presented
and methodically discussed, in conjunction with sensiti-
vity analysis to test their robustness. A checklist
(Table 1), containing its items, was developped on the
model described by Drummond et al. [11] and adapted
to COI by Molinier et al. [12]. An equal weight was
given to each item. The final score was the sum of the
eleven individual items.
Defining the disease and population
Illness costs widely depend on how the disease is
defined. AD diagnosis is based on Alzheimer’s Asso-
ciation criteria (NINCDS-ADRDA) [30] and Diagnostic
and Statistical Manual of Mental Disorders criteria
(DSM IV) [31]. As costs increase with disease severity
[32-35], disease stage must be specified and measured
using validated tools, as Clinical Dementia Rate [36]
(CDR) or Mini Mental State Examination (MMSE) [37].
Cost components may vary depending on the living con-
ditions (e.g. home, institution), and therefore must be
specified [33,38].
Epidemiological approach
Prevalence-based COI studies estimate the economic
burden to society during a period of time as a result of
the prevalence of the disease (e.g. in a given year).
Incidence-based studies estimate lifetime costs, and
measure the costs of an illness from diagnosis until re-
covery or another endpoint (e.g. death).
Perspective of the analysis and costs assessed
A COI study may be conducted from several perspec-
tives that must be specified to check that relevant costs
are included. From the healthcare payer perspective,
only direct costs incurred by a payer (e.g. national health
insurance) are considered. Indirect costs and the patient
“out-of-pocket” must also be included in a study which
uses societal perspective.
Estimating resource consumption
Resource consumption estimates vary depending on the
data available, but validated tools exist to collect them
[39]. In prospective COI studies, events have not occurred
yet, so data collection is done by the patients’ follow-up,
medical records, data from clinical trials and patients or
caregiver questionnaires. Conversely, in retrospective COI
study, events have already occurred, so data collection
must refer to recorded data, either using “Top-down”
method (aggregate figures from hospital admissions,
mortality, etc.) or “bottom-up” method (by referring to
the patients sample record).
Valuation of unit costs
The COI is estimated by identifying the cost-generating
components and by attributing them a monetary value.
This is the opportunity cost, the value of the forgone op-
portunity to use in a different way those resources that
are lost due to illness [11]. Direct and indirect costs
should be valued to assess the total economic COI. Di-
rect costs measure the resources used to treat an illness
and can be estimated by per capita expenditures, na-
tional tariffs, market prices, and published studies. Pa-
tient charges and tariffs do not give an accurate estimate
of the underlying costs. Market prices can be used to
value some cost categories like drugs, rehabilitation
items (e.g. eyeglasses, etc.). Direct costs can also be
valued with care facilities estimates, through the analy-
tical account system which specified distribution proper-
ties. Indirect costs measure the loss of productivity, the
effect of the illness on the patient or caregiver abilities
to work. Three methods are used to value indirect costs:
the Human Capital Approach (HCA) [40], the Friction
Cost Method [41] and the Willingness to pay approach
[42]. Informal care is an unpaid care often provided by
relatives and plays a substantial role in the AD patient’s
total care. Two methods are mainly used to value the
shadow price of informal care time. The opportunity
cost approach values the opportunity forgone as a result
of caregiving and the replacement cost approach values
the caregiving time spent at a price of a close substitute
[9,43,44].
Discounting costs
Discounting captures individual preferences for income
today rather than income in the future and is frequently
applied when COI studies are considered over several
years. In the USA, they estimate the discount rate at 3%
[45]. The following equation is applied to estimate costs:
Ca ¼ Ct
Xt
n¼1
1þ rð Þ
n
Where: Ca = present value of cost strategy, Ct = value of
cost strategy in year t, r = discount rate, t = time period.
Sensitivity analysis
Sensitivity analysis is recommended because COI studies
contain uncertainties. It allows testing the robustness of
the results by varying in range key variables (e.g., preva-
lence, unit costs, etc.) [46]. It seems more credible to
present a range of possible illness costs.
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Table 1 Answers to the methodological questions by study
All studies Lopez Bastida
et al. [13]
Coduras et al.
[14]
Rigaud et al.
[15]
Kronborg
Andersen et al. [16]
Cavallo et al.
[17]
Mesterton et al.
[18]
Kiencke et al.
[19]
Leon et al.
[20]
Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No
1 Was a clear definition of the
illness given?
10 5 2 P Yes Yes Yes No P P Yes
2 Were epidemiological sources
carefully described?
13 3 1 Yes Yes Yes Yes Yes P Yes Yes
3 Were costs sufficiently
disaggregated ?
12 0 5 Yes Yes No Yes Yes Yes Yes No
4 Were activity data sources
carefully described?
15 1 1 Yes Yes Yes Yes Yes Yes P Yes
5 Were activity data appropriately
assessed?
6 9 2 Yes P P P P Yes No Yes
6 Were the sources of all cost
values analytically described?
10 4 3 Yes Yes Yes Yes P Yes No Yes
7 Were unit costs appropriately
valued?
7 5 5 Yes Yes P P P Yes No Yes
8 Were the methods adopted
carefully explained?
11 6 0 Yes Yes Yes Yes P Yes P Yes
9 Were costs discounted ? 0 2 15 No No No No No No P No
10 Were the major assumptions
tested in a sensitivity analysis?
3 0 14 No Yes No No No No Yes No
11 Was the presentation of
study results consistent with
the methodology of study?
13 4 0 Yes Yes Yes Yes Yes Yes Yes P
12 Total score by study 100 39 48 8 1 2 9 1 1 6 2 3 7 2 2 4 4 3 7 2 2 4 4 3 7 1 3
Total score by study was the sum of answers; P, Partially.
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Table 1 Answers to the methodological questions by study (Continued)
Hay et al.
[21]
Rice et al.
[22]
Leon et al.
[23]
Ostbye et al.
[24]
Zencir et al.
[25]
Wang et al.
[26]
Suh et al.
[27]
Beeri et al.
[28]
Allegri et al.
[29]
Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No Yes P No
1 Was a clear definition of the
illness given?
No P Yes Yes Yes Yes P Yes Yes
2 Were epidemiological sources
carefully described?
Yes Yes P Yes P Yes Yes No Yes
3 Were costs sufficiently
disaggregated ?
Yes Yes No No Yes Yes No Yes Yes
4 Were activity data sources
carefully described?
Yes Yes Yes No Yes Yes Yes Yes Yes
5 Were activity data appropriately
assessed?
Yes Yes P No P P Yes P P
6 Were the sources of all cost
values analytically described?
Yes P P No P Yes Yes No Yes
7 Were unit costs appropriately
valued?
Yes P No No No Yes Yes No P
8 Were the methods adopted
carefully explained?
Yes P P P Yes Yes Yes P Yes
9 Were costs discounted ? P No No No No No No No No
10 Were the major assumptions
tested in a sensitivity analysis?
No No No No No No Yes No No
11 Was the presentation of
study results consistent with
the methodology of study?
P Yes Yes P Yes Yes Yes P Yes
12 Total score by study 7 2 2 5 4 2 3 4 4 2 2 7 5 3 3 8 1 2 8 1 2 3 3 5 7 2 2
Total score by study was the sum of answers; P, Partially.
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Presentation of results
The presentation of COI results should be consistent
with collected data and should disaggregate results into
as many components as possible with full explanations
given for clarity (Table 1).
Literature review
Study selection A bibliographic search was performed
on an international medical literature database (Medline).
All studies which assessed the economic burden of AD
were selected. To be exhaustive, eight keywords combi-
nations were employed: “Alzheimer disease” AND
“Cost of illness”; “Alzheimer disease” AND “Economic
evaluation”; “Alzheimer disease” AND “Cost study”;
“Alzheimer disease” AND “Cost analysis”; “Dementia”
AND “Cost of illness”; “Dementia” AND “Economic
evaluation”; “Dementia” AND “Cost study”; “Dementia”
AND “Cost analysis”. This search provided us 2271
papers. We kept the 2033 papers written in English.
Among them, we selected articles whose title contained
“Dementia” or “Alzheimer disease” (801 papers were
removed) AND “Costs” or “Expenses” or “Economic” or
“Burden” (another 941 papers were removed). This
study focused on the methodology used to estimate AD
costs, 137 papers were removed because they were
identified as global economic analyses. A hundred and
fifty four abstracts were first selected and 46 of them
underwent a subsequent full paper reading, thus
providing 17 articles. Figure 1 illustrates the literature
search, selection process, and presents reasons for
excluded studies.
Study review A systematic review was performed. One
author (N. Costa) selected abstracts. Six methodologists
read the 46 papers retrieved by the search strategy and
reviewed the 17 selected papers. With the key methodo-
logical points identified in the first part of the paper,
they asked questions based on existing checklists for full
economic evaluations [47]. The objective was not to es-
tablish a criteria hierarchy by using different weights,
but to use these criteria to analyze the methods used.
Each study was assessed separately by the reviewers.
Finally, a consensus was reached by discussion. Then,
all authors, both clinicians and methodologists, dis-
cussed the results.
Results
Seventeen studies met our criteria (Tables 2, 3). Seven
studies were conducted in Europe [13-19], 5 in North
America [20-24], 4 in Asia [25-28] and 1 in South America
[29]. Fifteen studies selected a sample ranging in size from
42 to 21512 patients [13-20,22-29].
Defining the disease and population
AD was defined with NINCDS-ADRDA criteria for 4
studies [20,23,28,29], with DSM criteria for 2 studies
[25,26], with both criteria for 4 studies [14-16,24] and with
ICD-10 for another study [19]. Six studies did not specify
the criteria used [13,17,18,21,22,27]. Disease severity was
measured with MMSE in 9 studies [14,15,18,22,24-28],
with CDR in 3 studies [13,16,23], and with both tests for 2
studies [20,29]. Disease severity was not specified in three
studies [17,21,23]. Four studies included community
dwelling patients [13,15,17,25] and 11 studies included both
patients in community and in institution [14,16,18,20-
24,27-29]. The place of living was not specified in 2 studies
[19,26].
Thirteen studies specified the mean age of the
sample of patients ranging from 70,5 to 81,8 years
[13-20,22,25,26,28,29].Two studies included patients
aged from 50 to over 80 years [21,24].
Perspective of the analysis and costs assessed
The adopted perspective was the society in 13 studies
[13-16,18,20-24,27-29] and respectively the family and
the healthcare payer in two studies [17,19]. Fourteen
studies quantified direct medical and non-medical costs
and informal costs [14,15,17,18,20-29]. Two studies did
not include inpatient costs [17,25]. Informal costs were
defined as direct non-medical costs in seven studies
[14,15,17,19,22,23,25] and as indirect costs in seven
studies [18,21,24,26-29]. One study quantified all the
costs (i.e. direct, informal and indirect) [13], indirect
costs were defined as patient early retirement and infor-
mal costs as direct non-medical costs. Danish study quan-
tified only direct medical and non-medical costs [16].
German study quantified only direct medical costs [19].
Estimating resource consumption
Three studies estimated resource consumption retro-
spectively [15,21,29]. Two of them used bottom-up ap-
proach to gather activity data through questionnaires
[15,29]. The other used a top-down approach, using
published national indicators, national surveys and pub-
lished studies [21]. Eleven studies estimated resource
consumption prospectively [13,14,16-18,20,22-24,26,28].
Two studies used mainly the Resource Utilisation in
Dementia (RUD) [48] to gather activity data [14,18],
completed with report forms, medical records and
questionnaires on 560 patients in the Spanish study
[14]. Nine studies gathered activity data mainly with ques-
tionnaires [13,16,17,20,22,23,25,26,28]. In the Danish
study, 164 AD couple (i.e. patients/caregivers) was inter-
viewed at home about Activities of Daily Living (ADL),
use of health care and community services [16]. Two US
studies measured direct costs using caregiver’s interviews
and Medicare Current Beneficiary Survey (MCBS) [13,23].
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Rice et al. gathered activity data through monthly care-
giver’s telephone interviews, billing records and with ca-
lendar given to caregiver at the baseline visit [23]. Israeli
study used a baseline questionnaire to record time spent
on caring and use of goods and services, and secondly
recorded the same items with 5 monthly telephone inter-
views [28]. Two studies recorded data via mailed question-
naires filled out by caregivers [13,17]. Turkish study used
a questionnaire and daily time sheets for caregiving time
[25]. Wang et al. interviewed 66 AD couples for filling out
the resource use’s questionnaire [26]. Two studies
used decision modelling [19,27] and estimated
resources with published sources and national surveys
[27] or with data extractions of a German retrospective
analysis [19]. One study did not precise the approach used
to gather activity data [24]. Eight studies specified the
number of caregiver included, several for 4 studies
[13,15,17,22] and only one for others [18,23,25,28]. Eight
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Figure 1 Literature search and selection process.
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Table 2 Cost of illness studie's characteristics in Alzheimer disease
Study Country Type of helthcare system
(insurance)
Year of
valuation
Currency Perspective Design of cost
analysis
Sample
size
Type of setting Follow-up
(months)
Total annual cost per
patient (US$)
Lopez Bastida et al.
[13]
Spain Public social 2001 € Societal Prosepective 237 At home 12 37,881
Coduras et al. [14] Spain Public social 2006 € Societal Prospective
multicentre
560 At home and in
institution
12 22,558
Rigaud et al. [15] France Public social 1996 € Societal Retrospective
single centre
48 At home 6 31,153
Kronborg Andersen
et al. [16]
Denmark Public social 1997 DKK Societal Prospective single
centre
164 At home and in
institution
12 17,078
Cavallo et al. [17] Italy Public and private 1995 Family Prospective single
centre
423 At home NS 52,954
Mesterton et al. [18] Sweden Public social 2007 SEK Societal Prospective
multicentre
233 At home and in
institution
1 46,956
Kiencke et al. [19] Germany Public health 2005 € Healthcare
payer
Decision model 21512 NS 60 11,786
Leon et al. [20] USA Private 1996 US$ Societal Prospective
multicentre
150 At home and in
institution
1 18,804
Hay et al. [21] USA Private 1983 US$ Societal Retrospective NS At home and in
institution
Lifetime 18,517*
Rice et al. [22] USA Private 1990 US$ Societal Prospective
multicentre
187 At home and in
institution
12 51,905*
Leon et al. [23] USA Private 1996 US$ Societal Prospective
multicentre
679 At home and in
institution
NS 27,672
Ostbye et al. [24] Canada Public social 1991 CAN$ Societal Not specify 10263 At home and in
institution
NS 13,900*
Zencir et al. [25] Turkey Public and private 2003 TRY NS Prosepective 42 At home 3 3,492
Wang et al. [26] China Public social insurance 2006 RMB NS Prospective single
centre
66 NS 12 2,935*
Suh et al. [27] Korea Private 2002 Societal Decision model NS At home and in
institution
12 11,389
Beeri et al. [28] Israel Public social 1999 NIS Societal Prospective
multicentre
121 At home and in
institution
6 19,893*
Allegri et al. [29] Argentina Public and private 2001 $Ar Societal Retrospective 100 At home and in
institution
3 7,709
NS: not specify; NA: not available, * Net Costs.
All costs are in US$ (1€ = 1,36491 US$, 1 CAN$ = 0,970458 US$, 1 DKK = 0,183360 US$, 1 RMB = 0,156987 US$; October 11, 2011) SEK, Swedish Crown; RMB, Yuan Renminbi; , Won; $Ar, Argentine Peso; NIS, New
Israeli Shekel; TRI, Turkish Lira; CAN$, Canadian Dollar; DKK, Danish Crown; €, Euro).
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Table 3 Total annual costs disaggregation
Study Total annual cost
per patient (US$)
Direct
medical
costs
Inpatient Outpatient Medication Specialized
institution
Other Direct non
medical costs
Home
help
Nursing
home
Transportation Other Informal
costs
Indirect
costs
Lopez Bastida
et al. [13]
37,881 4,848 924 844 2,468 301 311 2,306 2,223 NA 83 NA 29,884 843
Coduras et al.
[14]
22,558 4,744 144 503 2,137 1,97 NA 5,798 4,66 1,138 NA NA 12,016 NA
Rigaud et al.
[15]
31,153 6,663 NS NS NS NS NA 5,632 5,632 NS NS NA 18,858 NA
Kronborg
Andersen et al.
[16]
17,078 4,357 4,11 247 NA NA NA 12,721 12,663 NA NA 58 NA NA
Cavallo et al.
[17]
52,954 2,722 NA NA NA 2,722 NA 5,496 5,496 NA NA NA 44,736 NA
Mesterton et al.
[18]
46,956 3,155 1,067 1,118 970 NA NA 39,373 6,487 32,886 NA NA 4,428 NA
Kiencke et al.
[19]
11,786 11,786 2,889 1,449 2,126 NS 677 NA NA NA NA NA NA NA
Leon et al. [20] 18,804 7,284 NS NS NS NA NA NA NA NA NA NA 11,52 NA
Hay et al. [21] 18,517* 2,292 756 1,292 244 NA NA 7,285 1,774 5,326 167 18 9 NA
Rice et al. [22] 51,905* 22,176 1,072 545 301 19,521 737 9,699 9,585 NA NA 114 20,03 NA
Leon et al. [23] 27,672 21,924 NS NS NS NS NS NA NA NA NA NA 5,748 NA
Ostbye et al.
[24]
13,900* NS NS NS NS NS NS NS NS NS NA NS NS NA
Zencir et al. [25] 3,492 2,128 NA 37 2091 NA NA NA NA NA NA NA 1,364 NA
Wang et al. [26] 2,935* 863 29 32 802 NA 11 431 373 NA NA 27 1,63 NA
Suh et al. [27] 11,389 4,394 NS NS NS NA NA 445 445 NA NA NA 6,55 NA
Beeri et al. [28] 19,893* 3,974 1,749 1,63 584 NA 11 9,326 1,822 7,504 NA NA 6,593 NA
Allegri et al. [29] 7,709 3,389 525 280 2,389 NA 195 2,488 187 2,301 NA NA 1,832 NA
NS: not specify; NA: not available, * Net Costs.
All costs are in US$ (1€ = 1,36491 US$, 1 CAN$ = 0,970458 US$, 1 DKK = 0,183360 US$, 1 RMB = 0,156987 US$; October 11, 2011).
SEK, Swedish Crown; RMB, Yuan Renminbi; , Won; $Ar, Argentine Peso; NIS, New Israeli Shekel; TRI, Turkish Lira; CAN$, Canadian Dollar; DKK, Danish Crown; €, Euro).
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studies recorded AD net costs [15,16,21,22,24,26,28,29]
either by subtracting healthy patient costs or by asking
AD couple about resource’s used exclusively for AD.
The follow-up period was the lifetime in the study which
adopted the incidence-based approach [21] and was one
year in six studies [13,14,16,22,26,27], but was frequently
reduced to six, three or one month [14,18,20,25,28,29].
One study used a sixty months follow-up period [19].
Valuation of unit costs
Direct costs were estimated from published data, national
estimates and Medicare-over charges in one American
study [21], and from unit costs using the MCBS and na-
tional estimates for adult day care in another one [20].
Rice et al. used charges and bills provided by the care-
givers [22]. Two Spanish studies used the Spanish data-
base on medical costs (SOIKOS), patient’s reports and the
Spanish Vademecum to estimate unit costs [13,14]. Direct
unit costs were based on reimbursement tariffs used by
the French social health insurance and on the French Dis-
ease related group (DRG) for inpatient care [15]. The
Danish study used the reimbursement tariffs of social
insurance, hospital accounts, gross wage rates of pro-
fessionals and amortization procedure to value direct
costs [16]. Institutional costs were valued with the aver-
age cost per day without food and beverage. Zencir
et al. valued unit costs with the average price of public
and private physician visits and with the average price
per day for medication [25]. In the Chinese study, unit
costs were valued with drugs prices, transportation
reimbursements and local fees for home help [26]. Tariffs
of social health insurance and full drugstore prices were
used to unit costs valuation in the Argentinian study [28].
Meserton et al. valued unit costs with ward-specific per
diem costs from regional price, the lowest available price
for medication and with per visit costs [21]. For residential
care, the number of days in institution was multiplied by
the corresponding unit costs. Two studies used national
estimates to value unit costs [23,27]. No information relat-
ing to direct costs valuation was reported in four studies
[17-19,24]. Twelve studies used the replacement cost
approach to value informal care [13,15,17,20-26,28,29].
Seven studies used national estimates of a close substi-
tute [17,20-23,25,29]. Among these, 5 studies used dif-
ferent national wages to value different caregiver’s
activities [17,20,22,23,28]. Israeli study obtained differ-
ent hourly wage rates for each activity from the Central
Bureau of Statistics [28] and Leon et al. used hourly
wage of home health aids to value ADL time and
homemaker’s hourly wage to value IADL time [23].
Two studies used hospital nurse hourly wage [21,25],
another one, local wage rate without specifying the type
of professional caregiver [26] and the Canadian study
used published data [24]. Three studies did not specify
the sources used to value informal care time [13,15,29].
Nevertheless, one study used professional caregiver
monthly salary [29], another the cost per hour of a do-
mestic cleaner gross wage [13] and the last one the
average between housekeeping and paid assistance
wage [15]. One study chose opportunity cost approach
to value informal care, using the mean informal care-
giver own salary [14]. Both approaches were used in
one study [27]. The time spent by working caregivers
was valued with national estimates and the time spent
by working caregivers was valued with the own care-
givers salaries. Opportunity cost and revealed prefer-
ence approaches were used to value informal costs in
one study [18]. Caregiving time was valued either with
the HCA (working caregivers) or with a monetary esti-
mate value of one hour of leisure time (not working
caregivers). One study valued indirect costs with na-
tional estimates on employment and wages [13].
Discounting costs
One study has discounted costs without specifying the
discounting rate [21]. German study performed costs
discounting in the sensitivity analysis [19]. All the other
studies used a short follow-up period and had no need
to discount costs.
Sensitivity analysis
Only three studies performed a sensitivity analysis
[14,27,29]. One study analyzed the impact of informal
costs variation [14], another one the variation of AD suf-
ferers’ proportion according to the need of full time care
level [27], and the last one the discounting of the in-
curred costs [19].
Presentation of results
Most studies presented their results clearly. They were
mainly well explained and consistently set out in relation to
the methods adopted. Five studies did not sufficiently disag-
gregate costs, so the information strength was reduced
(Table 3) [15,20,23,24,27]. All studies presented results in
terms of cost per patient. Four studies proposed also AD
total costs for the country [13,23,24,27]. According to the
key methodological points, we have drafted a checklist of
questions related to the eight items analyzed (Table 1). For
9 studies, the answers of at least seven to eleven questions
were “yes” [13,14,16,18,20,21,26,27,29].
Conclusion
This study reviewed seventeen COI studies on AD with
the main goal of analyzing the various methodologies.
According to the key methodological points, nine studies
scored “yes” on the majority of the questions [13,14,16,
18,19,21,26,27,29].
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In this review, annual cost per patient varies from
$2,935 to $52,954, confirming the costly character of
AD. Nevertheless, commenting on these quantitative
results is a problem because different approaches have
been adopted. Informal care time varies widely accord-
ing to the tool used. Validated instruments such as RUD,
Caregiver Activity Survey (CAS) or Caregiver Activity
Time Survey (CATS) exist to estimate informal care
time [48-50]. Most often, time spent in ADL and IADL
was used but they measure dependence and not specific-
ally AD caregiving time. Opportunity cost underesti-
mates the time of women, elderly and minority that
suffer from discrimination in labour market [51], and
does not allow the valuation of different informal care-
giving activities. These activities change can be consid-
ered with the replacement cost approach. Informal costs
vary with the number of caregiver included. Informal
costs can be 8 times higher if several caregivers are
included rather than just one. AD informal costs have to
be rigorously quantified because they represent 36% to
85% of total costs [9].
Unlike clinical trial results, it is very difficult to generalize
results of economic studies conducted in different coun-
tries. Economic results are difficult to compare because of
monetary issues (i.e. fluctuating exchange rates, purchasing
powers of currencies). According to the World Bank classi-
fication [52], 3 studies in this review were conducted in
upper middle income economies [25,26,29] and presented
a mean annual cost for an AD patients which is 5 times
lower than in studies conducted in high income econ-
omies. Purchasing Power Parity (PPP) use could help
results comparison because it eliminates price levels differ-
ences between countries [53].
Domestic characteristics also affect resource consump-
tion and unit costs, including differences in clinical prac-
tice and healthcare system framework. For example,
medication costs can vary between studies because of
the use of tariffs in solidarity systems which are not
comparable to free prices in private systems.
Follow-up periods found in this review were often less
than one year, which is a short period to assess chronic
disease costs. However, data collection over a long period
is difficult so the use of models could compensate this
difficulty.
Some limitations are present in this review as only
English papers were selected, which restricted our sam-
ple. Another limitation is based on the lack of items
weighting (Table 1). It is likely that results are more sig-
nificantly affected by some items than others. Further
works must be performed in this area.
Nevertheless, this study built an inventory on the me-
thodology used to analyze AD costs and helped in better
understanding the reasons of disparate results between
studies.
COI results are the basis for economic evaluations and
provide information for models that is a part of any effi-
ciency evaluation [45]. Nevertheless, an insufficient de-
scription of methods may lead to misunderstandings.
COI studies identified in this review highlight the poor
consensus of methodological approaches. Medical jour-
nal should encourage researchers to give clear descrip-
tions and discuss limitations, and a further effort should
be made to validate methodology. The definition of
standards, with a large consensus in the methodology
selected to conduct this studies, should be a major con-
cern for the scientific community. A collective awareness
about disease burden exists between economists, policies
and caregivers that may lead to relevant decision making.
COI studies can serve as a basis for projecting disease
expenses, and thus allow adapting medical and social dis-
ease management in order to control AD costs.
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